Gilenya results 'exciting' for young MS patients

5 September 2017
2019_biotech_test_vial_discovery_big

Swiss pharma giant Novartis (NOVN: VX) has announced positive top-line results from a Phase III study investigating the safety and efficacy of oral once-daily Gilenya (fingolimod) in children and adolescents with multiple sclerosis (MS).

Data from the PARADIGMS study, the first ever randomized, controlled Phase III trial of a disease-modifying therapy in pediatric MS, shows a significant and clinically-meaningful reduction in the number of relapses in this patient population over a period of up to two years, compared to interferon beta-1a intramuscular injections.

The safety profile of fingolimod was consistent with that seen in other trials, with overall more adverse events reported in the group taking interferon beta-1a, a drug marketed by US biotech Biogen (Nasdaq: BIIB) under the brand name Avonex.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology